These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11475138)

  • 1. Safety of biologics: current issues and future concerns.
    Feagan BG
    Acta Gastroenterol Belg; 2001; 64(2):210-4. PubMed ID: 11475138
    [No Abstract]   [Full Text] [Related]  

  • 2. [Perianal herpes simplex in a patient with Crohn's disease treated with infliximab].
    López-Negre JL; Graells J; Orbeal R; Saavedra J; Parés D
    Gastroenterol Hepatol; 2010 Dec; 33(10):758-9. PubMed ID: 20932602
    [No Abstract]   [Full Text] [Related]  

  • 3. Infliximab therapy in Crohn's disease: safety issues.
    Hommes DW; van Deventer SJ
    Neth J Med; 2003 Apr; 61(4):100-4. PubMed ID: 12852717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
    Berg PA
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab (Remicade) for Crohn's disease.
    Med Lett Drugs Ther; 1999 Feb; 41(1047):19-20. PubMed ID: 10076592
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.
    Bousvaros A
    Expert Rev Clin Immunol; 2010 Jul; 6(4):659-66. PubMed ID: 20594138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-TNF antibodies in the treatment of intestinal inflammatory disease].
    Hinojosa J
    Gastroenterol Hepatol; 2000 May; 23(5):250-7. PubMed ID: 10902280
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biological compounds in the treatment of Crohn's disease].
    Dinari G
    Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to de Vries HE, Van Oijen MGH, de Jong DJ. Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol 2009;7:603-604.
    Caspersen S; Mortensen C; Riis L; Jess T; Bendtsen F
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1257. PubMed ID: 19778634
    [No Abstract]   [Full Text] [Related]  

  • 10. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update upon efficacy and safety of TNF-α inhibitors.
    Murdaca G; Colombo BM; Cagnati P; Gulli R; Spanò F; Puppo F
    Expert Opin Drug Saf; 2012 Jan; 11(1):1-5. PubMed ID: 22010813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody approved for treatment of Crohn's disease.
    Freeman TR; Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(6):770-2. PubMed ID: 9861797
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologics and infections: lessons from tumor necrosis factor blocking agents.
    Wallis RS
    Infect Dis Clin North Am; 2011 Dec; 25(4):895-910. PubMed ID: 22054762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of infliximab in inflammatory bowel disease needs to be debated.
    de Vries HS; Van Oijen MG; de Jong DJ
    Clin Gastroenterol Hepatol; 2009 May; 7(5):603-4. PubMed ID: 19166980
    [No Abstract]   [Full Text] [Related]  

  • 15. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Cottone M; Kohn A; Daperno M; Armuzzi A; Guidi L; D'Inca R; Bossa F; Angelucci E; Biancone L; Gionchetti P; Ardizzone S; Papi C; Fries W; Danese S; Riegler G; Cappello M; Castiglione F; Annese V; Orlando A
    Clin Gastroenterol Hepatol; 2011 Jan; 9(1):30-5. PubMed ID: 20951835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Indications for infliximab. How long should treatment last? Risk/benefit evaluation].
    Domènech Morral E
    Gastroenterol Hepatol; 2004 Mar; 27(3):172-6. PubMed ID: 14998471
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical outcome and safety of periodic infliximab therapy in children and adolescents with Crohn's disease.
    Diamanti A; Papadatou B; Knafelz D; Gambarara M; Ferretti F; Castro M
    J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):302-3. PubMed ID: 15319637
    [No Abstract]   [Full Text] [Related]  

  • 18. Biologics in peri-operative management of Crohn's disease.
    Hanauer SB
    Acta Gastroenterol Belg; 2001; 64(2):191-2. PubMed ID: 11475133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protocol for inducing infliximab tolerance in a patient with psoriatic spondylarthritis].
    Gallardo R; Fobelo MJ; Pastor C; Orta-Cuevas JC
    Farm Hosp; 2010; 34(2):94-6. PubMed ID: 20304368
    [No Abstract]   [Full Text] [Related]  

  • 20. Rare neurological condition linked to newer monoclonal antibody biologics.
    Kuehn BM
    JAMA; 2009 Apr; 301(14):1423-4. PubMed ID: 19351930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.